AU705031B2 - Composition for treating pain - Google Patents

Composition for treating pain Download PDF

Info

Publication number
AU705031B2
AU705031B2 AU12791/97A AU1279197A AU705031B2 AU 705031 B2 AU705031 B2 AU 705031B2 AU 12791/97 A AU12791/97 A AU 12791/97A AU 1279197 A AU1279197 A AU 1279197A AU 705031 B2 AU705031 B2 AU 705031B2
Authority
AU
Australia
Prior art keywords
carbon atoms
alkyl
alkoxy
substituted
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU12791/97A
Other languages
English (en)
Other versions
AU1279197A (en
Inventor
Charles H. Mitch
Harlan E Shannon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU1279197A publication Critical patent/AU1279197A/en
Application granted granted Critical
Publication of AU705031B2 publication Critical patent/AU705031B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU12791/97A 1995-12-07 1996-12-05 Composition for treating pain Ceased AU705031B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US829995P 1995-12-07 1995-12-07
US60/008299 1995-12-07
PCT/US1996/019309 WO1997020561A1 (en) 1995-12-07 1996-12-05 Composition for treating pain

Publications (2)

Publication Number Publication Date
AU1279197A AU1279197A (en) 1997-06-27
AU705031B2 true AU705031B2 (en) 1999-05-13

Family

ID=21730869

Family Applications (1)

Application Number Title Priority Date Filing Date
AU12791/97A Ceased AU705031B2 (en) 1995-12-07 1996-12-05 Composition for treating pain

Country Status (13)

Country Link
EP (1) EP0871445A4 (cs)
JP (1) JP2000501709A (cs)
KR (1) KR19990071976A (cs)
CN (1) CN1208349A (cs)
AU (1) AU705031B2 (cs)
CA (1) CA2238815A1 (cs)
CZ (1) CZ174698A3 (cs)
EA (1) EA199800533A1 (cs)
IL (1) IL124419A0 (cs)
NO (1) NO982562L (cs)
NZ (1) NZ324988A (cs)
PL (1) PL327137A1 (cs)
WO (1) WO1997020561A1 (cs)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6966998A (en) * 1997-04-11 1998-11-11 Eli Lilly And Company Composition for treating pain
AU5123200A (en) 1999-06-04 2000-12-28 Eli Lilly And Company 7-oxo-2-azabicyclo(2.2.1)heptanes as selective muscarinic receptor antagonist
JP6539274B2 (ja) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 押出成形された即放性乱用抑止性丸剤
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
WO2016064873A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
WO2020206410A1 (en) * 2019-04-04 2020-10-08 University Of Maryland, Baltimore Methods of using muscarinic antagonists in the treatment of depression

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2998450A (en) * 1958-05-19 1961-08-29 Warner Lambert Pharmaceutical Process of preparing nu-acetyl-p-amino phenol
GB8717446D0 (en) * 1987-07-23 1987-08-26 Merck Sharp & Dohme Chemical compounds
NZ225999A (en) * 1987-09-10 1992-04-28 Merck Sharp & Dohme Azacyclic- or azabicyclic-substituted thiadiazole derivatives and pharmaceutical compositions
US5260293A (en) * 1988-01-30 1993-11-09 Merck Sharp & Dohme Limited Pyrazines, pyrimidines and pyridazines useful in the treatment of senile dementia
IL89351A0 (en) * 1988-03-14 1989-09-10 Lundbeck & Co As H 4,5,6,7-tetrahydroisothiazolo(4,5-c)pyridines,process for their preparation and pharmaceutical compositions containing them
US5418240A (en) * 1990-08-21 1995-05-23 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
CA2185805A1 (en) * 1994-03-18 1995-09-28 Georg Frank Low dosage ketoprofen

Also Published As

Publication number Publication date
EP0871445A1 (en) 1998-10-21
NO982562D0 (no) 1998-06-04
NZ324988A (en) 1999-08-30
AU1279197A (en) 1997-06-27
CN1208349A (zh) 1999-02-17
EA199800533A1 (ru) 1999-02-25
CZ174698A3 (cs) 1998-10-14
CA2238815A1 (en) 1997-06-12
EP0871445A4 (en) 2001-01-10
KR19990071976A (ko) 1999-09-27
PL327137A1 (en) 1998-11-23
WO1997020561A1 (en) 1997-06-12
JP2000501709A (ja) 2000-02-15
NO982562L (no) 1998-07-10
IL124419A0 (en) 1998-12-06

Similar Documents

Publication Publication Date Title
BR112020014160A2 (pt) Compostos de benzamida
AU3768001A (en) A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
MX2007011436A (es) Ligando del receptor nicotinico neuronal 7 y composiciones antipsicoticas.
AU705031B2 (en) Composition for treating pain
WO2013002365A1 (ja) 止痒剤
KR20110021823A (ko) 진통 내성 억제제
WO2011122701A1 (en) Method for treating schizophrenia and related diseases
US20090197823A1 (en) Aliskiren modulation of neurogenesis
CA2582436C (en) Combinations of nicotinic acetylcholine alpha 7 receptor agonists
WO2002036113A1 (en) Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4)
AU715645B2 (en) Method for treating pain
WO1997020556A9 (en) Method for treating pain
RU2419433C2 (ru) Средство для профилактики или лечения алкогольной зависимости и зависимости от лекарственных веществ
EP1007041A1 (en) Composition for treating pain
US20190343839A1 (en) Mglu2/3 antagonists for the treatment of intellectual disabilities
WO1998046601A1 (en) Composition for treating pain
MXPA98004519A (en) Composition to treat do
US20090270400A1 (en) Painkilling association comprising a dihydroimidazopyrazine derivative
AU2009218456A1 (en) Combination comprising a cannabinoid receptor binding compound and an opioid
ZA200109049B (en) New pharmaceutically active compounds.

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired